EP300 and prostate carcinoma: p300/CBP bromodomain inhibitor CCS1477 is currently in early-phase clinical trials; thus, we tested the efficacy of CCS1477 and another bromodomain inhibitor, GNE-049, in AR-positive prostate cancer cells17,22.